(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 February 2022 (10.02.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/032020 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61K 47/26* (2006.01)
A61K 9/00 (2006.01) *A61P 35/00* (2006.01)
A61K 47/18 (2017.01)

(21) International Application Number:
PCT/US2021/044832

(22) International Filing Date:
05 August 2021 (05.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/062,740 07 August 2020 (07.08.2020) US

(71) Applicant: **FORTIS THERAPEUTICS, INC.** [US/US]; 11099 North Torrey Pines Road, Suite 290, La Jolla, California 92037 (US).

(72) Inventors: **NASOFF, Marc**; 11099 North Torrey Pines Road, Suite 290, La Jolla, California 92037 (US). **DORR, Andrew**; 11099 North Torrey Pines Road, Suite 290, La Jolla, California 92037 (US).

(74) Agent: **GROTE, Eric A.**; WILSON SONSINI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF




FIG. 5A

(57) Abstract: Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent. In one embodiment, the immunoconjugate is FOR46, which is a conjugate of the anti-CD46 antibody YS5FL to monomethylauristatin E (MMAE) through a maleimidocaproyl-valine-citrulline-para-amino benzyloxycarbonyl (mc-vc-PAB) linker.

WO 2022/032020 A1